Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberogast for heartburn in adults with functional dyspepsia
NL-OMON49070Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of Iberogast in functional dyspepsia (FD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: GORD symptom score improvement. Started Jun 2017; status: active, not recruiting.
02
Drugs
Iberogast
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NL-OMON49070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49070.